CN
Connect Biopharma Holdings Limited
CNTB · NASDAQ
$2.06 +3.52% (+$0.07)
1M -11.59%
Market Cap $129.7M
P/E Ratio -
Div. Yield -
ROE 95.51%
Bulios Fair Price
$1.24
39.8% downside
Current Price
$2.06
Undervalued Fair Value Overvalued
According to Bulios Fair Price, CNTB is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
1/9Valuation
33 /100
Expensive P/S 2,026.65x
P/B 3.09x
P/E N/A
Growth
0 /100
Declining Book val. growth 35.64%
EPS growth N/A
Rev. growth N/A
Profitability
20 /100
Weak Gross margin 100.00%
Net margin 86,687.50%
FCF margin 80,687.50%
Quality
0 /100
Poor ROIC 136.22%
ROE 95.51%
Asset turnover 0.00x
Debt
100 /100
Low Debt/Equity 0.02x
Current ratio 3.74x
Int. coverage N/A
Stability
19 /100
Unstable Beta -0.22x
EPS volatility 196.78%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about CNTB
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Barry D. Quart
Employees
64
Headquarters
San Diego
Upcoming events
11 NOV
Earnings
Upcoming earnings report